Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LEVI-04
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Levicept Completes Recruitment in Phase II Clinical Trial of Neurotrophin Modulator LEVI-04
Details : LEVI-04 is a novel neurotrophin-modulating biological agent. It is under phase 2 clinical development for the treatment of chronic pain in patients with osteoarthritis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 13, 2023
Lead Product(s) : LEVI-04
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LEVI-04 is a Other Large Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 16, 2022
Lead Product(s) : LEVI-04
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Hammersmith Medicines Research | MAC Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LEVI-04 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteoarthritis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 24, 2017
Lead Product(s) : LEVI-04
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Hammersmith Medicines Research | MAC Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable